Skip to content

NCBIO Blog

Stay up to date with the latest from NCBIO

Recent Posts

BIO: What happened with the Orphan Drug Tax Credit

September 17, 2021

During a busy week in Congress, Democrats included a change to the Orphan Drug Tax Credit that would negatively impact research on rare diseases affecting millions of Americans. The U.S. House of Representatives has several committees marking up the Senate’s $3.5 trillion budget reconciliation package. (Here’s BIO’s readout, including news on drug price controls and the…

Read More

BIO’s fall Congressional preview

September 8, 2021

The summer calm is grinding to a halt as members of Congress have returned to D.C. for what is sure to be a busy legislative sprint that could potentially impact all sectors of the biotech industry.

Read More

BIO: Where things stand with TRIPS waiver

August 19, 2021

It’s been a while since we’ve talked about what’s going on at the WTO. Here’s the latest news-and why the proposed waiver of vaccine IP is still a bad idea. The status: The World Trade Organization is still considering a proposal backed by India and South Africa (and supported by the U.S.) to waive the…

Read More

BIO: How the PASTEUR Act would support antibiotic R&D

June 22, 2021

The PASTEUR Act, legislation designed to make research and development of new antibiotics economically viable, was reintroduced in Congress last week with bipartisan support. Here’s what it would do and why it matters. Antimicrobial resistance is a big problem. AMR occurs when bacteria, viruses, fungi and parasites no longer respond to antibiotics. If we don’t…

Read More

Government price fixing for U.S. medicines will cost lives, jobs, innovation

May 13, 2021

Legislation like H.R. 3 that fixes prices for prescription medicines would limit patients’ access to new treatments while doing nothing to lower prices at the pharmacy counter.

Read More

Vaccine patent waiver breaks faith with American companies, stifles innovation

May 13, 2021

NCBIO is extremely disappointed that the Biden administration has chosen to support waiving critical intellectual property protections for U.S. COVID-19 vaccines. This decision, known as a TRIPS waiver, breaks faith with American innovators, punishes the ingenuity of our life sciences industry and will delay the equitable delivery of COVID vaccines to people around the globe.    …

Read More

BIO: Why the TRIPS waiver wouldn’t work

April 20, 2021

BIO President and CEO Dr. Michelle McMurry-Heath sent a letter April 19 to U.S. Trade Representative Ambassador Katherine Tai to explain why the WTO’s proposed “TRIPS waiver” would have global health and economic consequences as the pandemic rages on.

Read More

Executive order on drug prices does no favors for NC patients, hospitals

November 25, 2020

A new executive order that slashes Medicare payments to hospitals and physicians for certain medicines will hurt patients’ access to care and financially stress already overburdened hospitals and innovation-based pharmaceutical companies

Read More